智翔金泰(688443.SH)在研产品GR2301注射液的临床试验申请获批准

Core Viewpoint - The company, Zhixiang Jintai (688443.SH), has received approval from the National Medical Products Administration for the clinical trial of its product GR2301 injection, which is a recombinant fully human anti-IL-15 monoclonal antibody aimed at treating autoimmune diseases like vitiligo caused by IL-15 expression disorders [1] Group 1 - The clinical trial application for GR2301 injection has been approved [1] - GR2301 injection is developed independently by the company [1] - The mechanism of GR2301 involves blocking IL-15 interactions, which may help in treating autoimmune diseases [1]